In this article, we pharmacologically characterized two naturally occurring human histamine H 3 receptor (hH 3 R) isoforms, hH 3 R(445) and hH 3 R(365). These abundantly expressed splice variants differ by a deletion of 80 amino acids in the intracellular loop 3. In this report, we show that the hH 3 R(365) is differentially expressed compared with the hH 3 R(445) and has a higher affinity and potency for H 3 R agonists and conversely a lower potency and affinity for H 3 R inverse agonists. Furthermore, we show a higher constitutive signaling of the hH 3 R(365) compared with the hH 3 R(445) in both guanosine-5Ј-O-(3-[
sidered as potential new therapeutics and are currently undergoing clinical trails (Celanire et al., 2005) .
For a good understanding of the biological effects of H 3 R ligands, a detailed knowledge of the molecular pharmacology of the human H 3 R (hH 3 R) is indispensable. The molecular cloning of the hH 3 R (Lovenberg et al., 1999) has revealed that the hH 3 gene is located on chromosome 20 (20q13.32-20q13.33 ) and contains three introns (Cogé et al., 2001) , which give rise to a large number of hH 3 R isoforms through alternative splicing (for review, see Hancock et al., 2003; Leurs et al., 2005) . At present, there is no detailed knowledge on the pharmacological consequences of the various alternative splicing events. On the basis of the currently published information, one can conclude that the hH 3 R(365) is one of the most abundantly expressed hH 3 R isoforms next to the full-length hH 3 R(445) (Cogé et al., 2001; Wellendorph et al., 2002; Esbenshade et al., 2006) . The hH 3 R(365) isoform lacks 80 amino acids in the third intracellular loop (IL3) and has been described to be nonfunctional in a cAMP, guanosine-5Ј-O- (3- mobilization assay (Cogé et al., 2001) but to be functional in an R-SAT reporter assay (Wellendorph et al., 2002) . For other G-protein-coupled receptors (GPCRs), the IL3 has been shown to dictate G-protein specificity (Burstein et al., 1996; Senogles et al., 2004) and bind ␤-arrestins (Gelber et al., 1999) and calmodulin (Turner et al., 2004) . Furthermore, the carboxyl terminus of the IL3 has been shown to play a role in constitutive activity of GPCRs (Chakir et al., 2003) . In view of the relative high abundance of the hH 3 R(365) isoform and the known importance of the IL3 loop in GPCR-mediated signal transduction, we pharmacologically characterized the hH 3 R(445) and the hH 3 R(365) isoforms in full detail in this study.
Materials and Methods
Materials. Dulbecco's modified Eagle's medium, trypsin-EDTA, penicillin, L-glutamine, and streptomycin were from Invitrogen (Breda, The Netherlands), and fetal calf serum was from Integro (Zaandam, The Netherlands). Culture dishes were from Costar (Haarlemermeer, The Netherlands). cAMP was obtained from Sigma-Aldrich Chemie B.V. (Zwijndrecht, The Netherlands). All H 3 R ligands were (re-)synthesized at the Vrije Universiteit Amsterdam or at Abbott Laboratories. G-418 was obtained from Duchefa Biochemie B.V. (Haarlem, The Netherlands). 3-Isobutyl-1-methylxanthine was obtained from Acros (Fischer Scientific, 's Hertogenbosch, The Netherlands). N ␣ -[methyl-3 H]Histamine (83 Ci/mmol) was from PerkinElmer Life Sciences (Zaventem, Belgium) . [ 3 H]cAMP (40 Ci/mmol) was from Amersham (Hertogenbosch, The Netherlands). The following compounds were used: FUB322, A-304121, A-317920, A-320436, A-331440, A-349821, A-358239, and A-431404.
Cloning of the Histamine H 3 Receptor Isoforms. The human histamine H 3 receptor gene was cloned using human thalamus poly-A RNA (Clontech, Palo Alto, CA) with RT-PCR methods using primers designed according to the published human histamine H 3 receptor gene sequences (GenBank accession no. AF140538) (Lovenberg et al., 1999) . The cDNAs for the human full-length [hH 3 R(445)] and a shorter histamine H 3 receptor isoform [hH 3 R(365)], with an 80-amino acid deletion from the third intracellular loop, were cloned into the pCIneo expression vector.
Analysis of H 3 R Isoform Expression. Tissue expression of H 3 R isoforms was analyzed by RT-PCR. Human mRNA (1 g; Clontech, Mountain View, CA) was reverse-transcribed using SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA) and amplified for 35 cycles of 95°C for 45 s, 60°C for 1.5 min, 72°C for 2 min, and a final extension at 72°C for 7 min using 1 unit of Platinum Taq High Fidelity DNA polymerase (Invitrogen). The 5Ј forward and the 3Ј reverse primers used were F754 (nucleotides 754 -778) and R1406 (nucleotides 1383-1406) (Cogé et al., 2001) . The PCR products were subcloned into pCR Blunt II-TOPO cloning vector (Invitrogen) and sequenced. PCR products were analyzed using agarose gels stained with ethidium bromide.
Cell Culture. The H 3 R isoforms were stably expressed in rat C6 glioma cells and were maintained at 37°C in a humidified 5% CO 2 , 95% air atmosphere in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 2 mM L-glutamine, 50 IU/ml penicillin, and 50 g/ml streptomycin in the presence of 400 g/ml G-418.
Radioligand Binding. Cells were scraped from their dishes, centrifuged (3 min, 1000 rpm), and the pellets were stored at Ϫ20°C until use. Before use, the pellets were dissolved in 50 mM Na 2 HPO 4 , pH 7. H]A-349821 (ϳ0.01 -1.5 nM), and nonspecific binding was defined by 100 M thioperamide. The incubation was terminated by rapid filtration over polyethylenimine (0.3%)-pretreated Unifilter GF/C filter plates with two subsequent washes with ice-cold 50 mM TrisHCl, pH 7.4. Radioactivity retained on the filter was determined by liquid scintillation counting on the Microbeta Trilux with 25 l of Microscint "O."
GTP␥S Binding Assay. Human embryonic kidney cell membranes expressing the human H 3 R were prepared by homogenization in cold buffer containing 50 mM Tris-HCl, pH 7.4, 5 mM EDTA, 10 mM MgCl 2 , and protease inhibitors. The homogenate was centrifuged two times at 40,000g for 20 min at 4°C, and the resulting pellet was resuspended in buffer containing 50 mM Tris HCl, pH 7.4, 5 mM EDTA, and 10 mM MgCl 2 . Glycerol and bovine serum albumin were added to a final concentration of 10% glycerol and 1% bovine serum albumin before freezing the membranes. The inverse agonist activity of H 3 R antagonists was determined as described previously (Krueger et al., 2005) . In brief, membranes were diluted in GTP␥S assay buffer (25 mM HEPES, 2.5 mM MgCl 2 , and 75 mM NaCl, pH 7.4), and 10 g of membrane protein was incubated in a 96-well deep-well block in the presence of 5.0 M unlabeled GDP, approximately 0.5 nM [ 35 S]GTP␥S, and various concentrations of H 3 R antagonists. Samples were subsequently incubated at 37°C for 20 min. For assays to determine antagonist activity, (R)-␣-methylhistamine (30 nM) was added in addition to the assay components described above, and the samples were incubated at 37°C for 5 min. The assays were terminated by the addition of cold buffer (50 mM Tris-HCl, 75 mM NaCl, and 2.5 mM MgCl 2 , pH 7.6) and subsequent harvesting by vacuum filtration onto a Packard Unifilter 96-well GF/B plate (PerkinElmer Life Sciences). After extensive washing, the plates were dried, Microscint 20 was added to the samples, and the amount of bound [ 35 S]GTP␥S was determined utilizing the Topcount (PerkinElmer Life Sciences, Boston, MA). The percentage of [
35 S]GTP␥S bound in each sample was calculated as a percentage of that bound to control samples incubated in the absence of histamine H 3 R ligands. Triplicate determinations were obtained at each concentration, and the data were analyzed using GraphPad Prism (GraphPad Software, San Diego, CA) to obtain EC 50 or IC 50 values and Hill slopes. pK b values were calculated using the generalized Cheng-Prusoff equation (Cheng and Prusoff, 1973; Leff and Dougall, 1993) . The mean Ϯ S.E.M. of at least three independent experiments is reported.
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at ASPET Journals on July 10, 2017 jpet.aspetjournals.org Measurement of cAMP. C6 cells stably expressing the H 3 R were washed once with DMEM supplemented with 25 mM HEPES (pH 7.4 at 37°C) and preincubated in the same medium for 30 min at 37°C. Thereafter, 5 ϫ 10 3 cells/50 l was added per well to a 96-well plate containing the respective ligands in 50 l of DMEM supplemented with 0.3 mM 3-isobutyl-1-methylxanthine and 1 M forskolin (final concentration, 0.5 M). After 10 min, incubations were terminated by the addition of 20 l of 0.3 mg/ml saponin to each well to lyse the cells. Subsequently, cAMP levels were determined with a competitive protein kinase A (PKA) binding assay, as described. Protein kinase A-containing fraction was isolated from bovine adrenal glands, as described previously . In brief, a PKA-containing fraction was isolated from bovine adrenal glands, which were homogenized in 10 volumes of 100 mM Tris-HCl, 250 mM NaCl, 10 mM EDTA, 0.25 M sucrose, and 0.1% 2-mercaptoethanol (pH 7.4 at 4°C) and centrifuged for 60 min at 30.000g at 4°C. The supernatant, containing PKA, was carefully recovered and frozen in 1-ml aliquots at Ϫ80°C. Before use, the PKA was diluted 12-fold in ice-cold phosphate-buffered saline (PBS) and kept on ice. To each well, 20 l of 0.6 nM [
3 H]cAMP in PBS (48.0 Ci/mmol) and 60 l of PKA in PBS was added. After 30 min, the reaction was terminated by filtration over Unifilter GF/B filter plates with two subsequent washes with 200 l of ice-cold 50 mM Tris-HCl, pH 7.4. Retained radioactivity was determined by liquid scintillation counting on the Microbeta Trilux with 50 l of Microscint "O." The amount of cAMP in each sample was calculated with GraphPad Prism version 4.01 for Windows (GraphPad Software), using a generated standard cAMP curve (0.1 mM-10 pM).
Statistical Analysis. Statistical analyses were performed using GraphPad Prism version 4.01 for Windows (GraphPad Software). Differences among means were evaluated by analysis of variance, followed by the Dunnett's post test. For all analyses, the null hypothesis was rejected at the 0.05 level.
Results
Differential Expression in the Central Nervous System. The relative expression of the hH 3 R(445) and hH 3 R(365) isoforms was assessed by RT-PCR in several areas of the human CNS. For the hH 3 R(445), high expression was found in the cerebellum and the caudate, and moderate expression was found in the hypothalamus, cerebrum, and thalamus ( Fig. 1 ). Low expression was found in all other tested regions, and very low expression was found in the spinal cord. In most of the tested regions, the hH 3 R(365) was found to be approximately 1.4-fold higher expressed than the hH 3 R(445). The biggest differences in expression for the two isoforms was found in the regions where the hH 3 R(445) was higher expressed than the hH 3 R(365), such as the caudate (3.5-fold) R(445) , K d ϭ 0.081 Ϯ 0.01 nM, n ϭ 4; and hH 3 R(365), K d ϭ 0.10 Ϯ 0.02 nM, n ϭ 4], but a significant difference was again found for the maximal number of binding sites [hH 3 R(445), B max ϭ 1800 Ϯ 100 fmol/mg protein, n ϭ 4; and hH 3 R(365), B max ϭ 780 Ϯ 100 fmol/mg protein, n ϭ 4] (Fig. 2, C and D (Fig. 2F) .
Pharmacological Profile of Radioligand Binding to the hH 3 R(445) and hH 3 R(365) Isoforms. A series of imi- Fig. 1 . Expression of the hH 3 R(445) and the hH 3 R(365) isoforms identified in the human central nervous system by RT-PCR. A and B, mRNA of human brain tissues was amplified by RT-PCR using primers flanking the intronic region. PCR products were analyzed using agarose gels stained with ethidium bromide. The lengths of amplicons were estimated by molecular mass markers. B, human GAPDH amplification was used as an internal standard. Table 1 ). The competition binding curves for all compounds were best fitted according to a single binding site model and shown to have Hill slopes close to unity for both radioligands (Fig. 3, A-D Table 2 ). The dose-response curves for all compounds were best fitted according to a single binding site model and showed to have Hill slopes close to unity (Fig. 4,  A-E) . Potencies of the agonists correlated highly (r 2 ϭ 0.96) and were found to be, on average, 4.6-fold more potent at the hH 3 R(365) (Fig. 4F) . However, the maximal increase in [ 35 S]GTP␥S binding for full agonists was approximately 80% lower at the hH 3 (365) (1.2-fold increase of basal) compared with the hH 3 R(445) (2.2-fold increase of basal) (Fig. 4, A-C) .
Potencies of the tested inverse agonist correlate highly as well (r 2 ϭ 0.99) but were found to be, on average, 2.6-fold less potent at the hH 3 R(365) (Fig. 4F) . Interestingly, nonimidazole ligands, like A-349821, showed a significantly (p Ͻ 0.01) higher inhibition of basal [
35 S]GTP␥S binding for the hH 3 R(365) compared with the hH 3 R(445) (Fig. 4, D and E) .
Pharmacological Profile of the Forskolin-Induced cAMP Levels by the hH 3 R(445) and the hH 3 R(365). Histamine H 3 R-specific compounds were also tested for their modulation of cAMP levels in forskolin (0.5 M)-stimulated C6 cells expressing either the hH 3 R(445) or the hH 3 R(365) (see Table 3 ). All tested agonists and inverse agonists potencies correlate highly (r 2 ϭ 0.91 and 0.88, respectively). Agonists are approximately 35-fold more potent at the hH 3 R(365) (Fig. 5F ). Similar to the [ 35 S]GTP␥S binding assay, full agonists are, however, more efficacious at the hH 3 R(445) (80 and 44% inhibition of the forskolin-induced cAMP production, respectively; see Fig. 5, A-C) . Conversely, inverse agonists are approximately 14-fold less potent at the at ASPET Journals on July 10, 2017 jpet.aspetjournals.org Downloaded from hH 3 R(445) but appear more efficacious (Fig. 5, D and E) . Especially, nonimidazole compounds, like A-349821, showed increased efficacy at the hH 3 R(365) (3.0-fold increase over basal) compared with the hH 3 R(445) (1.5-fold increase over basal) (Fig. 5D ). 
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at ASPET Journals on July 10, 2017 jpet.aspetjournals.org cells expressing the hH 3 R(445) was comparable with the parental cell line, whereas for the hH 3 R(365), the basal increase was significantly higher (Fig. 6, A-D) . Stimulation of the hH 3 R(445) with the H 3 R agonist (R)-␣-methylhistamine led to a steep increase in [ (Fig. 6B) . On membranes expressing the hH 3 R(365), the increase in [ 35 S]GTP␥S binding induced by (R)-␣-methylhistamine was moderate, whereas the effect of A-349821 was more pronounced compared with its effect at the hH 3 R(445) (Fig. 6,  A-D) .
In addition, forskolin (0.5 M)-induced cAMP levels were 2.3-fold (p Ͻ 0.001) lower in C6 cells expressing the hH 3 R(365) compared with C6 cells expressing hH 3 R(445) (Fig. 6E) . The H 3 R agonist (R)-␣-methylhistamine inhibited the forskolin (0.5 M) induced to a similar absolute level in both hH 3 R(445)-and hH 3 R(365)-expressing C6 cells. Likewise, stimulation of C6 cells expressing either the hH 3 R(445) or the hH 3 R(365) with the H 3 R inverse agonist A-349821 increased the cAMP levels to a similar absolute level of cAMP.
Application of the Cubic Ternary Model to Explain the Observed Properties of the hH 3 R(365) and hH 3 R(445).
We used the cubic ternary complex (CTC) model (Weiss et al., 1996a,b,c) to examine whether the observed differences in affinities and potencies, the maximal number of binding sites of agonist and inverse agonist and the effect of GDP on the maximal number of binding sites could all be explained by an increase in GPCR constitutive activity, represented in the CTC TABLE 3 Potency values from a cAMP formation assay in C6 cells expressing hH 3 R(445) or hH 3 R(365) model by the equilibrium constant of the receptor (K act ; see Fig. 7A ).
To examine the maximal number of binding site as found with the H 3 R radioligands ( Fig. 2A) , the agonist radioligand N ␣ -[methyl-3 H]histamine was assumed to bind the R a and R a G state of the receptor, to promote receptor activation (␣ Ͼ 1), and to facilitate G-protein coupling only for the receptor in its active form (␦ Ͼ 1). The inverse agonist radioligand [
3 H]A-349821 was assumed to bind the R i and R i G state of the receptor, to inhibit receptor activation (␣ Ͻ 1), and to facilitate G-protein coupling only for the receptor in its inactive form (␦ Ͻ 1). Furthermore, to examine whether the difference between the two isoforms could be due to a difference in K act , the hH 3 R(445) and the hH 3 R(365) were assumed to have a K act Ͻ 1 and K act ϭ 1, respectively. Hereby, the hH 3 R(445) exists predominantly in the R i conformation, and the hH 3 R(365) has no preference for either the R a of R i conformation. Experimentally, we found an approximately 3-fold difference in maximal number of binding sites of [
3 H]A-349821 for the two hH 3 R isoforms (Fig. 2D) . To take this observation into account in the CTC model, the R tot of the hH 3 R(365) was assumed to be 3-fold lower compared with the hH 3 R(445).
Subsequently, the maximal number of binding sites for the agonist, N ␣ -[methyl-3 H]histamine (N␣MH), and inverse agonist, [
125 I]iodophenpropit (IPP), were simulated in the presence (G tot ϭ 1) and absence (G tot ϭ 0) of G-proteins. This simulation revealed that only the maximal number of binding sites for the agonist, reflected by the receptor states LR a and LR a G, on the hH 3 R (445) is affected by the removal of G-proteins (Fig. 7B) . Furthermore, the maximal number of binding sites for the hH 3 R(445) recognized by the inverse agonist, reflected by the receptor states LR i and LR i G, was found to be approximately three times higher, whereas for the hH 3 R(365), agonist and inverse agonists give rise to the same maximal number of binding sites (Fig. 7B) . To account for the differences in ligand affinity and potency found experimentally for the hH 3 R(445) and the hH 3 R(365), we calculated the apparent affinity constant when G-proteins are not limiting (K Aapp ) (Weiss et al., 1996b) .
From this equation (eq. 1), it follows that for the hH 3 R(445), the log(K Aapp ) for agonists is 10.2 and for inverse agonists, 10.0; in the case of the hH 3 R(365), the log(K Aapp ) was increased for agonists to 11.0 and decreased for inverse agonists to 9.0. We defined a partial agonist to have an ␣ Ͼ 1 but lower than ␣ of a full agonist, e.g., the ligand is able to activate the receptor but to a lesser extent than a full agonist. The difference for partial agonists in the K Aapp for the two isoforms decreases, and with an ␣ Ϸ 1, the log(K Aapp ) ϭ 10 for both the hH 3 R(445) and the hH 3 R(365).
Furthermore, we simulated radioligand competition and dose-response curves for the hH 3 R(445) and hH 3 R(365) in a G-protein-dependent manner (Monczor et al., 2003) . For the competition curves, we assumed the radioligands and the competing ligands to have properties as described above. Subsequently, the concentration of a ligand (L) was varied, and the generated curves were plotted as percentage of the B max for both hH 3 R isoforms and radioligands (Fig. 7, C and D) .
For simulation of dose-response curves, we assumed that both the LR a G and R a G give rise to a receptor response (as described by Chen et al., 2000) . Subsequently, the following 2) was used to simulate the dose-response curves (Fig. 7E ).
Furthermore, when [L] ϭ 0, the above equation describes the basal signaling of the receptor, and this was found to be 19-fold increased for the hH 3 R(365) compared with the hH 3 R(445).
agonists can activate the hH 3 R(365) isoform, resulting in an increase in [
35 S]GTP␥S binding and the expected inhibition of forskolin-induced cAMP. The apparent discrepancy between the results of Coge et al. and the present study might be due to the high constitutive activity of the hH 3 R(365), which makes it difficult to measure agonist-mediated responses. Interestingly, the study of Coge et al. does not report on the functional effects of H 3 R inverse agonists on the hH 3 R(365).
The hH 3 R(365) displays higher potencies and affinities for agonists and likewise lower potencies and affinities for inverse agonists, consistent with an increase in constitutive activity. These findings are in line with previous observations with the rat H 3 R B and rat H 3 R C isoforms, which have a 32-or 48-amino acid deletion in the IL3 loop, respectively, and also display a slightly higher affinity and potency for agonists compared with the full-length rat H 3 R A isoform (Morisset et al., 2000; Drutel et al., 2001) . Interestingly, partial agonists have a higher affinity and potency at the hH 3 R(365) as well but to a less extent than full agonists. The observed statistical outliers in the binding affinity correlation plots, in fact, appear to be partial agonists with intrinsic activities between 0.0 and 0.4 or 0.0 and 0.7 in the correlation plots for N Table 3 ). This is in good agreement with the CTC model simulations, where we found that the ␣ of a compound correlates with the difference in apparent affinity (K Aapp ) for the two isoforms, e.g., a decrease in ␣ leads to a smaller difference in K Aapp for the two hH 3 R isoforms. Interestingly, agents that prevent G-protein coupling were found to affect the maximal number of binding sites of N ␣ -[methyl-3 H]histamine only for the hH 3 R(445) but not for the hH 3 R(365). In the present study, the binding of the inverse agonists was unaffected by a treatment that would uncouple the receptor from the G-protein. This seems in contrast with earlier studies but is most likely due to increased ionic strength of the incubation buffers, which is known to shift the equilibrium of the receptor to the inactive conformation (Costa et al., 1990) . To account for these observations, the CTC model was used to examine whether a higher K act of a constitutively active receptor might be able to explain these observations. Indeed, the CTC model can account for the observed different maximal number of binding sites for the different radioligands and confirmed that the number of agonist-labeled sites was affected only at the hH 3 R(445) when [G tot ] ϭ 0. Furthermore, an increase of the K act resulted in the experimentally observed increase of potency and affinity of agonists and decreased potency and affinity of inverse agonists at the hH 3 R(365) compared with the hH 3 R(445). The CTC model also accounted for the intermediate shift in affinity of partial agonists, showing that the preference over the hH 3 R(365) is dependent on intrinsic activity of the compounds. We used the CTC model because other "simpler" models, such as the extended ternary complex model, could not explain the effect of GDP. In this model, the removal of the G-protein affects predominantly the receptor with the biggest K act , which is not in accordance with our experimental observations. In summary, our experimental and CTC modeling data indicate that the hH 3 R(365) isoform mainly functions in a constitutive manner. These data indicate that the 80-amino acid stretch in the third intracellular loop either imparts a negative constraint on the GPCR activation directly or is involved in the interaction of intracellular proteins that inhibit H 3 R activation. Future studies should address the role of the 80-amino acid stretch in the IL3 on H 3 R receptor function in more detail. Because the H 3 R is one of the few examples for which GPCR constitutive activity has been shown to be prominent under in vivo conditions (Morisset et al., 2000; Wieland et al., 2001 ), our present results suggest that this effect might be mainly mediated by the hH 3 R(365) isoform. The nonimidazole compounds show a higher negative intrinsic activity at the hH 3 R(365) compared with classical imidazole containing compounds like thioperamide. In combination with the potential differential expression in the CNS, this might lead to specific effects of these nonimidazole inverse agonists in brain areas where the hH 3 R(365) is higher expressed than the hH 3 R(445).
